Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations

EFPIA Newsletter 7 April 2022


Shortening the WAIT - Patient Access to Medicines in Europe

EFPIA WAIT Indicator Survey

Disparities in the time it takes for patients to access new medicines in different EU Member States are increasing.

Published today, the most comprehensive EFPIA WAIT Indicator Survey to date found that the average time to reimbursement for innovative treatments across EU and European Economic Area (EEA) countries continues to be as long as 511 days. Patients in Germany wait around 133 days to access new medicines compared to patients in Romania that endure a wait of more than 899 days.

Read more


New EFPIA report on the cost of pharmaceuticals


Are medicines affordable for health systems? The myths, the facts and the way forward
07 April 2022

Pharmaceutical expenditure has been stable as a share of total healthcare expenditure in all European countries included... Read more


Data contribution initiative


Industry Pioneers the Contribution of Substance Data to decrease animal testing
04 April 2022

A new initiative will make available previously unpublished data on chemicals tested to develop medicines. Read more


World Health Day

Rising temperatures and sea levels, increasing CO2 levels, extreme weather affect people’s health. Find out more about what the pharmaceutical industry is doing to tackle climate change and build a #HealthierTomorrow


What we are reading


AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals...
On 04 April 2022 (AMR Action Fund)

Deals mark an important step toward the goal of bringing two to four new antibiotics to market to take on growing threat... Read more

The COVID-19 Pandemic Is Bad. Could it Have Been Even Worse?
On 25 March 2022 (Think Global Health)

A look at how pre-pandemic health-care trends affected COVID-19 mortality rates. Read more

Finance, culture, talent: why Europe struggles to commercialise its biotech expertise
On 21 March 2022 (Financial Times)

The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard... Read more